Social anxiety disorder

被引:675
作者
Stein, Murray B. [1 ,2 ,3 ]
Stein, Dan J. [4 ]
机构
[1] Univ Calif San Diego, Anxiety & Traumat Stress Disorders Res Program, Dept Psychiat, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA
[3] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
[4] Univ Cape Town, Dept Psychiat, ZA-7925 Cape Town, South Africa
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
D O I
10.1016/S0140-6736(08)60488-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our understanding of social anxiety disorder (also known as social phobia) has moved from rudimentary awareness that it is not merely shyness to a much more sophisticated appreciation of its prevalence, its chronic and pernicious nature, and its neurobiological underpinnings. Social anxiety disorder is the most common anxiety disorder; it has an early age of onset-by age 11 years in about 50% and by age 20 years in about 80% of individuals-and it is a risk factor for subsequent depressive illness and substance abuse. Functional neuroimaging studies point to increased activity in amygdala and insula in patients with social anxiety disorder, and genetic studies are increasingly focusing on this and other (eg, personality trait neuroticism) core phenotypes to identify risk loci. A range of effective cognitive behavioural and pharmacological treatments for children and adults now exists; the challenges lie in optimum integration and dissemination of these treatments, and learning how to help the 30-40% of patients for whom treatment does not work.
引用
收藏
页码:1115 / 1125
页数:11
相关论文
共 139 条
[61]   A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder [J].
Liebowitz, MR ;
Mangano, RM ;
Bradwejn, J ;
Asnis, G .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (02) :238-247
[62]   Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study [J].
Liebowitz, MR ;
DeMartinis, NA ;
Weihs, K ;
Londborg, PD ;
Smith, WT ;
Chung, H ;
Fayyad, R ;
Clary, CM .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (07) :785-792
[63]  
LIEBOWITZ MR, 1992, ARCH GEN PSYCHIAT, V49, P290
[64]   A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder [J].
Liebowitz, MR ;
Stein, MB ;
Tancer, M ;
Carpenter, D ;
Oakes, R ;
Pitts, CD .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (01) :66-74
[65]   DIFFERENT AGES OF ONSET IN VARIETIES OF PHOBIA [J].
MARKS, IM ;
GELDER, MG .
AMERICAN JOURNAL OF PSYCHIATRY, 1966, 123 (02) :218-&
[66]   Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder [J].
Massion, AO ;
Dyck, IR ;
Shea, T ;
Phillips, KA ;
Warshaw, MG ;
Keller, MB .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (05) :434-440
[67]  
Matsunaga H, 2001, INT J NEUROPSYCHOPH, V4, P231, DOI 10.1017/S1461145701002474
[68]   Using five questions to screen for five common mental disorders in primary care: diagnostic accuracy of the Anxiety and Depression Detector [J].
Means-Christensen, AJ ;
Sherbourne, CD ;
Roy-Byrne, PP ;
Craske, MG ;
Stein, MB .
GENERAL HOSPITAL PSYCHIATRY, 2006, 28 (02) :108-118
[69]   Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale [J].
Mennin, DS ;
Fresco, DM ;
Heimberg, RG ;
Schneier, FR ;
Davies, SO ;
Liebowitz, MR .
JOURNAL OF ANXIETY DISORDERS, 2002, 16 (06) :661-673
[70]   Neural correlates of genetically abnormal social cognition in Williams syndrome [J].
Meyer-Lindenberg, A ;
Hariri, AR ;
Munoz, KE ;
Mervis, CB ;
Mattay, VS ;
Morris, CA ;
Berman, KF .
NATURE NEUROSCIENCE, 2005, 8 (08) :991-993